Please login to the form below

Not currently logged in
Email:
Password:

Aveo Oncology

This page shows the latest Aveo Oncology news and features for those working in and with pharma, biotech and healthcare.

Aveo’s tivozanib is knocked back by FDA once again

Aveo’s tivozanib is knocked back by FDA once again

Try as it might, Aveo Oncology just can’t persuade the FDA to accept a new regulatory filing for its kidney cancer candidate tivozanib. ... analysis at 263 events, and that the median OS for tivozanib is worse than that of sorafenib", notes Aveo.

Latest news

  • AVEO warns EU approval of Fotivda could be at risk AVEO warns EU approval of Fotivda could be at risk

    Concerns arose with overall survival data. AVEO Oncology has revealed in a regulatory filing that European Medicines Agency (EMA) approval for its Fotivda kidney cancer drug could be at risk of ... AVEO’s European licensee EUSA Pharma has been

  • Relay Therapeutics strengthens team Relay Therapeutics strengthens team

    Bergstorm joins the biotech from Mersana Therapeutics, where he led the advancement of two oncology products. ... He has held roles for Keryx Biopharmaceutical, Algeta ASA and AVEO Oncology.

  • NICE backs EUSA's RCC treatment Fotivda NICE backs EUSA's RCC treatment Fotivda

    cases. EUSA licenced Fotivda from Aveo Pharmaceuticals back in 2015, but although it has European approval in advanced renal cell carcinoma it failed to gain approval from the US Food and ... However, Aveo Oncology is looking to re-file Fotivda in the

  • Novartis licenses cancer support drug from Aveo Oncology Novartis licenses cancer support drug from Aveo Oncology

    Novartis is paying up to $326m to license rights to a drug developed by Aveo Oncology designed to treat a debilitating symptom of cancer and other diseases. ... Under the terms of the deal, Aveo stands to receive up to $311m in milestones as well as

  • FDA turns down tivozanib for kidney cancer FDA turns down tivozanib for kidney cancer

    Agency describes data provided by Aveo Oncology and Astellas as "uninterpretable". ... The US FDA has declined to approve Aveo Oncology and Astellas' kidney cancer drug tivozanib, saying the results of a pivotal trial supporting the application were

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2016 Deal Watch March 2016

    Collaboration – marketing &distribution. $171. AVEO Oncology/ CANbridge Life Sciences. AV-203; ErbB3 (HER3) inhibitory antibody for oesophageal cancer. ... Harvard University/ Merck &Co. Oncology – transcription regulating enzymes for leukaemia

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    Research collaboration. 275. Definiens / AstraZeneca (through MedImmune). Tissue Phenomics Dx oncology biomarkers. ... Acquisition of voucher. 125. AVEO Oncology / Ophthotech Corporation. VEGF tyrosine kinase inhibitor tivozanib.

  • Pharma deals during February 2014 Pharma deals during February 2014

    In another termination of an oncology deal, Astellas exercised its right to terminate its collaboration with Aveo Oncology to develop the tyrosine kinase inhibitor, tivozanib, for “strategic reasons”. ... Innate Pharma will prioritise development of

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Guide
How to embrace behavioural science principles in healthcare MR...
Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...